Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Allergan announced the launch of Saphris (asenapine) 2.5mg sublingual tablets as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients aged 10–17 years.
Saphris, a second generation atypical antipsychotic, is also indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy or as adjunctive therapy with either lithium or valproate. The efficacy of asenapine may be mediated through a combination of antagonist activity at D2 and 5-HT2A receptors.
RELATED: Saphris OK’d for Pediatric Use in Bipolar I Disorder
Saphris for pediatric patients is available in 2.5mg sublingual black cherry flavored tablets.
For more information call (800) 678-1605 or visit Saphris.com.
